PMID- 38088519
OWN - NLM
STAT- MEDLINE
DCOM- 20240313
LR  - 20240313
IS  - 2410-8650 (Electronic)
IS  - 1607-551X (Linking)
VI  - 40
IP  - 3
DP  - 2024 Mar
TI  - Camrelizumab in combination with neoadjuvant chemotherapy in resectable locally 
      advanced esophageal squamous carcinoma cancer: Results from a retrospective 
      study.
PG  - 291-295
LID - 10.1002/kjm2.12793 [doi]
AB  - This study aimed to evaluate the safety and efficacy of camrelizumab combined 
      with chemotherapy during preoperative neoadjuvant therapy in patients with 
      locally advanced resectable esophageal squamous cell carcinoma (ESCC) of clinical 
      Stages II and III. The patients received camrelizumab plus chemotherapy regimen 
      on Day 1 for up to three to four cycles (3 weeks per cycle). The probabilities of 
      overall survival (OS) were 55.6% at 12 months and 35.6% at 18 months (45 
      patients). The disease-free survival (DFS) rates were 70.0% at 12 months and 
      63.3% at 18 months (30 patients). The median OS and DFS were not reached. The 
      proportion of patients at postneoadjuvant pathological tumor stages ypT0, ypT2, 
      and ypT3 were 10 (33.3%), 14 (46.7%), and 6 (20.0%), respectively, and those at 
      stages ypN0 and ypN1 were 19 (63.3%) and 11 (36.7%), respectively. Additionally, 
      the pathological complete response rate was 33.3% (95% confidence interval [CI]: 
      0.154-0.512), and the major pathologic response rate was 46.7% (95% CI: 
      0.277-0.656). Grade >/=3 adverse events (AEs) were reported in five patients 
      (11.1%), with vomiting being the most common AE (three patients; 3.3%). Other 
      common AEs of any grade included decreased lymphocyte count (48.9%), reactive 
      capillary endothelial proliferation (46.7%), decreased white blood cell count 
      (40.0%), anemia (31.1%), and vomiting (31.1%). The combination of camrelizumab 
      and neoadjuvant chemotherapy in patients with locally advanced resectable ESCC 
      demonstrated promising efficacy and acceptable safety.
CI  - (c) 2023 The Authors. The Kaohsiung Journal of Medical Sciences published by John 
      Wiley & Sons Australia, Ltd on behalf of Kaohsiung Medical University.
FAU - Kang, Ning-Ning
AU  - Kang NN
AD  - Department of Thoracic Surgery, The First Affiliated Hospital of Anhui Medical 
      University, Anhui, China.
FAU - Zheng, Hao
AU  - Zheng H
AD  - Department of Thoracic Surgery, The First Affiliated Hospital of Anhui Medical 
      University, Anhui, China.
FAU - Hu, Jin-Xiu
AU  - Hu JX
AD  - Department of Thoracic Surgery, The First Affiliated Hospital of Anhui Medical 
      University, Anhui, China.
FAU - Cui, Kai
AU  - Cui K
AD  - Department of Thoracic Surgery, The First Affiliated Hospital of Anhui Medical 
      University, Anhui, China.
FAU - Si, Pan-Pan
AU  - Si PP
AD  - Department of Thoracic Surgery, The First Affiliated Hospital of Anhui Medical 
      University, Anhui, China.
FAU - Ge, Wei
AU  - Ge W
AUID- ORCID: 0009-0007-4676-0020
AD  - Department of Thoracic Surgery, The First Affiliated Hospital of Anhui Medical 
      University, Anhui, China.
LA  - eng
GR  - NO. 2022xkj157/Anhui Medical University Fund/
PT  - Journal Article
DEP - 20231213
PL  - China (Republic : 1949- )
TA  - Kaohsiung J Med Sci
JT  - The Kaohsiung journal of medical sciences
JID - 100960562
RN  - 73096E137E (camrelizumab)
RN  - 0 (Antibodies, Monoclonal, Humanized)
SB  - IM
MH  - Humans
MH  - *Esophageal Squamous Cell Carcinoma/drug therapy/surgery
MH  - Neoadjuvant Therapy
MH  - Retrospective Studies
MH  - *Esophageal Neoplasms/drug therapy/surgery
MH  - *Carcinoma
MH  - Vomiting
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - *Antibodies, Monoclonal, Humanized
OTO - NOTNLM
OT  - Neoadjuvant therapy
OT  - efficacy
OT  - esophageal squamous cell carcinoma
OT  - immunotherapy
OT  - safety
EDAT- 2023/12/13 12:43
MHDA- 2024/03/13 06:46
CRDT- 2023/12/13 09:04
PHST- 2023/11/14 00:00 [revised]
PHST- 2023/06/29 00:00 [received]
PHST- 2023/11/16 00:00 [accepted]
PHST- 2024/03/13 06:46 [medline]
PHST- 2023/12/13 12:43 [pubmed]
PHST- 2023/12/13 09:04 [entrez]
AID - 10.1002/kjm2.12793 [doi]
PST - ppublish
SO  - Kaohsiung J Med Sci. 2024 Mar;40(3):291-295. doi: 10.1002/kjm2.12793. Epub 2023 
      Dec 13.